Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 39 Issue 1, January 2021

Resilient off-the-shelf T cells

Colored scanning electron micrograph of resting human T lymphocytes. Mo et al. present an alloimmune defense receptor that allows allogeneic T cells to resist rejection by the host immune system by deleting activated host T and NK cells.

See Mo et al.

Image: Steve Gschmeissner/Science Photo Library/Getty. Cover Design: Erin Dewalt.

Editorial

  • Emergency Use Authorizations for two mRNA COVID-19 vaccines represent a turning point in the pandemic. They also herald a new era for vaccinology.

    Editorial

    Advertisement

Top of page ⤴

News

Top of page ⤴

Correspondence

Top of page ⤴

Obituary

Top of page ⤴

Features

  • Patents

    • Biosimilar manufacturing process patent applications first filed more than a year after the biologic is approved, which represent the largest source of patent assertions in biosimilar litigation, could be addressed without requiring intervention by either the courts or Congress.

      • Arti K. Rai
      • W. Nicholson Price II
      Patents
    • Recent patents regarding the preparation, amplification and therapeutic use of circular RNA.

      Patents
Top of page ⤴

News & Views

Top of page ⤴

Research

Top of page ⤴

Amendments & Corrections

Top of page ⤴

Careers & Recruitment

  • Career Feature

  • People

    • Recent moves of note in and around the biotech and pharma industries.

      People
Top of page ⤴

Search

Quick links